Ceapro Inc V.CZO

Alternate Symbol(s): CRPOF

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > Phase 1

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Nov 27, 2023 2:41pm

66 Views

Post# 35754892

RE:Phase 1

Tencents wrote: And it's 10 to 15 years to get anything from phase 1 to market

With safety/tolerability and preliminary efficacy data for a product already believed safe given the history of avenanthramide a licensing deal with pharma could be significant given the large market.

"Pending successful results in the Phase 1 and potential Phase 2a study, we believe we will be well-positioned for out-licensing opportunities for later stage development and commercialization." news release

CZO has also scaled up its avenanthramide malted technology for the neutraceutical market. It can now produce what four plants could from the same input. Neutraceuticals can have a relatively short distance to market. CZO already has human data for exercise inflammation. CZO's clinical pill trial could help provide additional hints to support neutraceutical development such as concerning blood glucose for diabetics, blood pressure, inflammation, etc.

"Based on our results, we have confirmed for the first time that the glucose uptake is indeed inhibited by the presence of avenanthramides, suggesting the possibility of incorporating avenanthramides in foods to enhance postprandial glucose response, and ultimately improve the management of diabetes." The inhibition of intestinal glucose absorption by oat-derived avenanthramides - PubMed (nih.gov)

<< Previous

Bullboard Posts

Next >>

Red Light Holland and PharmAla notch psilocybin extraction